We examined the 21-aminosteroid U74006F, a potent inhibitor of lipid peroxidation, for potential neuroprotective effects in a canine model of complete cerebral ischemia. Two 1.5-mg/kg boluses were administered to six dogs, the first bolus 15 minutes prior to a 12-minute episode of complete cerebral ischemia and the second bolus after 11 minutes of ischemia, 1 minute prior to reperfusion. Using this dosage regimen, plasma U74006F levels of >0.3 ju.g/ml were maintained for up to an hour postischemia. An additional six animals received equal volumes of the citrate vehicle solution. At 24 and 48 hours postischemia, the dogs were neurologically evaluated by an observer blinded as to treatment selection. All six U74006F-treated animals had a normal neurologic outcome at 48 hours postischemia, while the citrate vehicle-treated animals all suffered moderate to severe neurologic deficits. The difference in outcome was significant at both 24 and 48 hours (/?< 0.005). Although U74006F is a 21-aminosteroid, it is not reported to possess glucocorticoid activity. This is supported by the present finding that no changes in plasma glucose concentration were observed following administration of the drug. The systemic vitamin £ levels of citrate vehicle-treated animals decreased significantly (from 4.10±0.46 /tg/ml to 2.95±0.38 jug/ml, /><0.05), whereas the vitamin £ levels in U74006F-treated animals did not decrease significantly. These results suggest that U74006F may be of benefit in improving neurologic outcome when administered prior to an episode of complete cerebral ischemia. It is possible that the neuroprotective effect observed in the present study is related to the free radical scavenging properties of this 21-aminosteroid. (Stroke 1991;22:902-909)
T he development of therapeutic strategies for
preservation of cerebral function following cardiac arrest is an area of great interest to clinicians.
1 -2 Studies have demonstrated that up to 50% of successfully resuscitated cardiac arrest victims sustain permanent neurologic impairment. 3 Factors contributing to neuronal injury following complete cerebral ischemia include not only those that occur during the period in which cerebral blood flow (CBF) is absent, but also those occurring during the early recirculation period when CBF is altered. In the clinical setting, the immediate definitive treatment for an ischemic event is to restore CBF and to otherwise optimize oxygen delivery to the ischemic brain. Further appropriate therapy is not well defined, although the calcium channel blocking agent nimodipine has recently shown promise in improving neurologic outcome following complete cerebral ischemia in primates 4 and stroke in man. 5 During the recirculation period a number of phenomena are thought to occur that may contribute to the ultimate neuronal injury. These include 1) transient postischemic hyperemia and hyperoxia 6 - 7 followed by a prolonged period of decreased CBF (the delayed postischemic hypoperfusion state), 89 2) decreased intracellular pH and adenosine 5'-triphosphate concentration, 3) influx of calcium into neurons, 4) increased concentrations of excitatory amino acids extracellularly, 10 and 5) release of free fatty acids from phospholipids. 11 While less well established, 11 there is some evidence that free radicals may also contribute to postischemic neuronal injury. 12 " 16 The hypothesis that oxygen free radicals play a role in postischemic neuronal damage predicts that interventions that decrease their production or propagation should improve neuronal survival and neurologic outcome. In a canine model of complete cerebral ischemia, deferoxamine alone 17 and a combination of superoxide dismutase and catalase 18 have failed to improve neurologic outcome. A combination of superoxide dismutase and deferoxamine was reported to enhance the recovery of somatosensory evoked potentials after 7 minutes of cardiac arrest in dogs, but the effect of this treatment on functional outcome in this model is unknown. 19 These data suggest that 1) free radicals do not play a major role in either postischemic cell damage in the central nervous system (CNS) or in functional neurologic outcome, 2) the free radical scavenging agents used are not being delivered to the sites at which oxygen free radicals are being generated and propagated, 3) the time at which the agents are administered does not coincide with the generation and propagation of oxygen free radicals, or 4) the scavenging efficiency, the dose, or the plasma half-life of the agents used is too low to demonstrate therapeutic efficacy. Desirable characteristics in a free radical scavenging agent might thus include lipid solubility, an ability to rapidly reach sites of free radical generation and damage (including the intracellular space), a high scavenging efficiency, and an absence of side effects. In addition, the drug must be present at the time of free radical generation.
A new class of oxygen free radical scavenging agents, the 21-aminosteroids, has recently been developed. 20 In addition to being nonpolar, these compounds are also highly efficient inhibitors of lipid peroxidation and do not possess glucocorticoid activity. 20 Of the 21-aminosteroids currently under investigation, U74006F {21-[4-(2,6-di-l-pyrrolidinyl-4-pyrimidinyl)-l-piperazinyl]-16 a-methyl-pregna-l,4,9(ll)-triene-3,20-dione; monomethane sulfonate; Upjohn Co., Kalamazoo, Mich.} has been the most widely studied. In addition to its in vitro effect on iron-dependent lipid peroxidation, U74006F blocks arachidonic acid release in mouse pituitary tumor cells. 21 Animals treated with U74006F had an improved outcome following trauma to the head and spinal cord in mouse and cat injury models, respectively. 22^3 Using a cardiac arrest model for complete cerebral ischemia, Natale et al 24 have reported reduced systemic lipid peroxidation and improved neurologic outcome in U74006F-treated dogs compared with placebo-treated animals. U74006F-treated gerbils had improved survival and histopathologic outcome following unilateral carotid artery occlusion. 25 The above results suggest that treatment with this highly efficient oxygen free radical scavenging drug improves neurologic and histopathologic outcome following CNS trauma and cerebral ischemia. The current study is designed to determine if U74006F administered intravenously prior to an episode of complete cerebral ischemia will decrease neurologic damage in an established dog model. 26 This model has the advantage of virtually eliminating any confounding systemic effects on animal outcome, an important consideration in view of the fact that free radicals are also thought to play a role in myocardial damage following cardiac arrest.
Materials and Methods
The protocol was approved by the institutional Animal Care and Use Committee. Twelve unmedicated, fasting adult mongrel dogs of either sex weighing 10-15 kg were studied. The animals were anesthetized with 1% halothane in 60-70% nitrous oxide and oxygen. Pancuronium (0.1 mg/kg i.v.) was given to facilitate endotracheal intubation and was thereafter given every 45 minutes at a dose of 0.05 mg/kg to maintain muscle paralysis. Ventilation was controlled using a Harvard pump (South Natick, Mass.), a tidal volume of 15-20 ml/kg, and a rate adjusted to maintain PacO2 at 35-40 mm Hg. End-expired P02, PCO2, halothane, and nitrous oxide concentrations were monitored with a mass spectrometer (PerkinElmer 1100 Medical Gas Analyzer, Norwalk, Conn.). Cannulas were inserted into the right femoral artery for blood sampling and continuous measurement of mean arterial blood pressure (MABP) and a forelimb vein for drug and fluid administration. Arterial blood gases were determined by electrodes at 37°C (Instrumentation Laboratory 1303, Dayton, Ohio). Blood oxygen contents were calculated from measurement of oxyhemoglobin concentrations (IL 282 CO-oximeter, Instrulab, Inc., Dayton, Ohio) and oxygen tensions. NaHCO 3 was administered intravenously to keep the buffer base (BB + ) near 40 meq/1. The electrocardiogram was recorded using two needle electrodes placed in the upper extremities. A fourlead, two-channel bifrontal and biparietal electroencephalogram (EEG) was recorded intermittently from subperiosteal platinum needle electrodes. Body temperature was measured with an esophageal thermistor and was maintained at 37±0.4°C with warming blankets. Blood glucose concentration was determined by a membrane-bound enzyme technique (Yellow Springs Instruments Model 23A Glucose Analyzer, Yellow Springs, Ohio).
A modification 26 of a previously described 27 compression model of "bloodless" global cerebral ischemia was used to avoid the adverse and possibly confounding systemic effects of either aortocaval occlusion or cardiopulmonary arrest models of complete cerebral ischemia. While the dogs were anesthetized with halothane and nitrous oxide, a 35-cmlong 1.52-mm-i.d. polyethylene catheter was inserted into the lumbar subarachnoid space and 3-5 ml of 1% tetracaine was administered to produce high spinal anesthesia. A 16-gauge Tuohy needle was inserted into the cisterna magna for later infusion of 37°C saline and continuous measurement of cerebrospinal fluid (CSF) pressure. At the conclusion of all procedures, the dog's eyes were taped shut and the ears filled with cotton. Halothane was then discontinued, and nitrogen was substituted for the nitrous oxide. When the end-expired halothane concentration was <0.1%, nitrous oxide concentration <5%, Pac>2 > 150 mm Hg, and Paco 2 near 38 mm Hg, control physiologic measurements were made. Fifteen minutes prior to the onset of cerebral ischemia, 1.5 mg/kg i.v. U74006F in a citrate buffer (n=6) or an equivalent volume of citrate buffer alone (n=6) were administered as a bolus. All dogs received 600,000 units penicillin and 500 mg streptomycin intramuscularly shortly after the induction of anesthesia.
After measurement of control physiologic variables, hypotension (systolic pressure <60 mm Hg) was induced using 0.5-5.0 mg i.v. trimethaphan. Positive end-expiratory airway pressure (5 cm PEEP) was maintained during the interval of induced hypotension. When systolic pressure reached 60 mm Hg, CSF pressure was rapidly increased (within 3-5 seconds) using simultaneous infusion of 37°C saline into the cisterna magna and the lumbar subarachnoid space. Cisternal CSF pressure was maintained at >20 mm Hg greater than systolic pressure for 12 minutes, during which time the EEG was isoelectric. A norepinephrine infusion was used as needed to maintain MABP near 40-60 mm Hg. A second dose of either U74006F or the citrate vehicle was administered 11 minutes after the beginning of the ischemic interval.
After exactly 12 minutes of an isoelectric EEG, the subarachnoid infusion conduits were opened to air and MABP was increased to >60 mm Hg within 1 minute postischemia using a norepinephrine infusion when necessary. Blood samples for determining plasma U74006F, vitamin E, and glucose concentrations were taken at regular intervals following the second intravenous bolus of U74006F or citrate vehicle. Animals were transiently hyperventilated and given sodium bicarbonate and supplemental oxygen as required to normalize pH, PaO2, and BB + . At 30 minutes postischemia, the lumbar subarachnoid catheter and the cisternal Tuohy needle were removed. Mechanical ventilation was continued until spontaneous ventilation maintained PacOj at <45 mm Hg and PaO2 at >55 mm Hg on room air. The dogs were then extubated and observed. Arterial blood gases were measured at 15-30 minutes postextubation and, when the blood gases met the above criteria, the dogs were returned to their cages. The dogs were examined every 8-10 hours thereafter and received food and water p.o. ad libitum and/or an intravenous infusion of 5% dextrose in lactated Ringer's solution (15 ml/kg) as determined by physical examination. Because of the noninvasive nature of this protocol, postischemic narcotic administration was unnecessary.
An observer blinded to the drug treatment scored the animals neurologically at 24 and 48 hours postischemia. A detailed neurologic scoring system 28 was used wherein the following were scored individually: consciousness, motor function, respiration, cranial nerves, and spinal nerves. A maximum of 100 points was possible and signified brain death, while a normal animal scored 0 points. The animal's score was converted to percent neurologic function by subtraction of the outcome score from 100. After final neurologic scoring at 48 hours the dogs were killed with an intravenous bolus of thiopental and KC1. Postmortem examinations of the heart, lungs, and brain were performed in all dogs. Plasma vitamin E and U74006F contents were determined by high-performance liquid chromatography (Waters, Milford, Mass.) using a previously described extraction procedure. 24 An electrochemical detector setting of 0.8 V was used to detect vitamin E or U74O06F in the eluate.
The physiologic variables measured just prior to the administration of either U74006F or an equal volume of the citrate vehicle served as control values. Repeated-measures analysis of variance was used to ascertain whether a change in any of the physiologic variables within a treatment group achieved significance. The Student-Newman-Keuls test was used to compare postischemic physiologic variables with control values. U74006F-and citrate vehicle-treated animals were compared using Student's t test for unpaired data. Statistical comparison of neurologic outcome between U74006F-treated and citrate vehicle-treated dogs was made using the Mann-Whitney rank sum test. A probability value of less than 0.05 was considered adequate to reject the null hypothesis. Data are presented as mean±SEM.
Results
Administration of U74006F at the times and dosages described above resulted in a plasma concentration of 2.48 ±0.56 Aig/ml at 5 minutes postischemia. The plasma concentration decreased thereafter but remained >0.30 fig/ml for 60 minutes (Figure 1) . No U74006F was detected in the plasma of drug-treated animals at 90 minutes postischemia. Similarly, no U74006F was detected in the citrate vehicle-treated animals.
Complete cerebral ischemia, as judged by the loss of all electrical activity on the EEG, was obtained 10±6 seconds after infusion of 37°C saline into the subarachnoid space resulted in a CSF pressure greater than the systolic pressure. A CSF pressure greater than the systolic pressure was easily maintained with a slow infusion of normothermic saline into the cisterna magna, and the EEG remained isoelectric throughout the period of the subarachnoid infusion in all animals studied. Physiologic variables measured were well matched between U74006F-treated and placebo-treated dogs with the exception of PaO2, PacOz, and pH at 5 minutes postischemia (Table 1) . This difference between groups was no longer significant at 30 minutes postischemia. The heart rate was significantly increased from control values for both groups at 1 minute postischemia and remained increased for up to 30 minutes postischemia in placebo-treated animals. Both placebo-treated and U74006F-treated dogs experienced a postischemic increase in plasma hemoglobin concentration (Hgb). This increase in Hgb was significant (p<0.01) only in placebo-treated animals and persisted for the duration of the immediate postischemic interval (Table 1 ). There was no significant difference (p>0.l at 1 and 30 minutes postischemia) in Hgb between drug-and placebotreated animals. Esophageal temperatures were well matched between treatment groups and showed no significant change during the study period in either group. Dogs from both treatment groups were extubated uneventfully within 15 minutes of the 2-hour postischemia physiologic measurements.
Plasma glucose concentration was not significantly different between treatment groups at any time and remained within a range of 50-114 mg/dl throughout the immediate postischemic period. The plasma glucose concentration for U74006F-treated dogs showed a trend for gradual increase ( Table 1) that achieved significance at 2 hours postischemia (79 ±8 mg/dl versus 86±5 mg/dl for placebo and U74006F-treated dogs, respectively; p<0.05) but remained at all times within the normal physiologic range. Placebo-treated animals showed a similar gradual increase in plasma glucose concentration, but this increase did not achieve significance.
Neurologic outcome scoring revealed a significantly greater deficit in placebo-treated dogs than in U74006F-treated animals at both 24 hours (data not shown, /?<0.005) and 48 hours (Figure 2 , /><0.005) postischemia. At 48 hours postischemia, all U74006F-treated animals had a normal neurologic outcome score. This is in contrast to placebo-treated animals, which had moderate to severe deficits at 48 hours postischemia, ranging from gait ataxia to spasticity in the hind limbs, decreased level of consciousness, and an inability to walk. None of the animals died during the 48 hours following the ischemic insult. Autopsy revealed no subarachnoid blood, areas of obvious cerebral infarct, or trauma to neurologic structures adjacent to the cisterna magna.
Plasma vitamin E levels were not significantly different between treatment groups prior to the administration of U74006F or placebo (4.21 ±0.56 and 4.10±0.46 ^.g/ml, respectively). Postischemic vitamin E levels decreased significantly (Figure 3 ) to 2.95±0.38 Mg/ml (p<0.05) in placebo-treated dogs. Vitamin E levels decreased numerically, but not significantly, to 3.62±0.52 jig/ml in U74006F-treated animals. This difference in vitamin E levels between treatment groups was significant (p<0.05) and persisted throughout the immediate (2 hours) postischemic period.
Discussion
Direct in vivo evidence for ischemia-related free radicals in the CNS has not been obtained to date. Descriptions of the time course and localization of free radical generation in the CNS has thus largely been inferred from what is thought to occur in other organ systems. In both isolated perfused hearts 29 and in vivo, 30 there is now direct evidence that free radical species are generated during reperfusion of ischemic myocardium in a burst-like fashion, generation peaking within 10-15 seconds after reflow and gradually declining thereafter. 31 Pretreatment with a hydroxyl free radical scavenger improved myocardial function and attenuated free radical production with reperfusion. 30 While these results have finally provided direct support from an intact organ for the hypothesis that free radicals are generated in a burst-like fashion following reperfusion, 32 they provide no information about the source of these free radicals and about what effect, if any, this burst of free radical activity has on postischemic cell survival. A recent study by Zweier et al 14 has also directly demonstrated that free radicals are generated in intact endothelial cells following anoxia and reoxygenation. Reoxygenation following anoxia generated a burst of oxygen free radical species (reaching a half-maximum value after 8 minutes) that was abolished by prior treatment with either superoxide dismutase or catalase. Marked inhibition of oxygen free radical generation was also observed with the potent xanthine oxidase inhibitor oxypurinol. 14 In that study an improved anoxic endothelial cell survival was correlated with a decrease in free radical generation following reoxygenation. Bearing in mind that these results were obtained using dispersed endothelial cell cultures and that anoxia/reoxygenation may not be an adequate model for ischemia/reperfusion in vivo, it is at least plausible that free radical-mediated vascular endothelial damage in the CNS may contribute to postischemic neuronal damage. Of the in situ evidence for free radical activity following ischemia in the CNS, the most suggestive is that of Watson et al, 12 who showed that lipid peroxidation is induced by reversible global ischemia. This effect was detected only when very small brain tissue samples were analyzed and was not apparent when larger or hemispheric rat brain tissue samples were used for the analysis of lipid peroxide levels.
Using a compressive model of complete cerebral ischemia for 12 minutes in dogs, we have demonstrated that pretreatment with two 1.5-mg/kg doses of the 21-aminosteroid U74006F resulted in a significant improvement in neurologic outcome at 24 and 48 hours postischemia compared with a citrate vehicle-treated group. The neurologic outcome in this model is not confounded by possible contributions of other organ system failure, a problem that is often faced in cardiac arrest. Thus, while the model employed here is less like the situation that occurs when a person experiences a cardiac arrest, it does permit the examination of the effects of a specific intervention on a specific organ system, in this case the CNS. The neurologic outcome results reported here are in agreement with the improvement in animal survival and 24-hour neurologic outcome previously reported 24 in a cardiac arrest model of complete cerebral ischemia. The plasma level of U74006F achieved with the dosage regimen employed was >0.3 /xg/ml for more than an hour, demonstrating that significant levels of the drug remained during the critical reperfusion period when a possible burst of free radical generation is thought to take place.
The two treatment groups were well matched in all physiologic variables with two exceptions. During the immediate postischemic interval, there was a moderate metabolic acidosis in the placebo-treated group that was not present in the U74006F-treated group. In addition, the placebo-treated animals experienced a 41% increase in Hgb, while U74006F-treated animals experienced no significant increase in Hgb. A similar increase in Hgb using this model of compressive ischemia was observed in an earlier study 26 and was attributed to mobilization of blood from the spleen, a major blood reservoir in dogs. 33 Because both groups of animals were well matched before ischemia and were treated identically during the study, it is possible that these differences reflect a U74006F-related effect. We can offer no pharmacologic explanation for these differences. It should be emphasized that while Hgb in the placebo-treated group remained significantly elevated during the 2-hour postischemic interval, it did not differ significantly (with the exception of the 60 minutes postischemia value) from that observed in the U74006F-treated group. Thus, it is unlikely that the significant difference in neurologic outcome between groups was related to differences in Hgb.
The possibility that U74006F might increase plasma glucose concentration prior to the onset of complete cerebral ischemia and thus adversely affect neurologic outcome 34 was considered. Measurement of the plasma glucose concentration before and after administration of U74006F but prior to the episode of complete cerebral ischemia revealed no significant change in plasma glucose levels during the preischemic period. As shown in Table 1 , there was a gradual increase in plasma glucose concentration that differed significantly from the preischemic control value, but not from that in the placebo-treated group, at 2 hours postischemia. At all times mean plasma glucose concentration remained within the normal physiologic range. In view of a similar gradual increase in plasma glucose concentration observed in the placebo-treated group, it is unlikely that this increase reflects a drug-related effect. These results confirm that U74006F possesses no significant glucocorticoid activity. 21 ' 24 U74006F is a potent inhibitor of lipid peroxidation in rat brain homogenates, comparing well with vitamin E and butylated hydroxytoluene in inhibitory potency. 20 U74006F also markedly inhibits peroxidation of purified low density lipoproteins exposed to Fenton's reagent. 20 U74006F-mediated inhibition of lipid peroxidation does not involve iron chelation; rather, the drug acts by directly scavenging the lipid peroxyl radical and superoxide, 21 ' 25 a profile resembling that of vitamin E. U74006F differs from vitamin E in that its activity as a free radical scavenger is greatly enhanced by the presence of intact biological membranes, whereas vitamin E is equally effective in the presence of either less polar solvents or systems containing biological membranes. 20 In addition, U74006F has been shown to decrease the ferrous chloride-and iodoacetate-induced release of arachidonic acid from cultured mouse pituitary cells. 21 The improvement in neurologic outcome observed in the present study may be related to the free radical scavenging properties of U74006F. The systemic vitamin E levels, possibly an index of free radical activity during the ischemic period, was significantly decreased in placebo-treated animals. A similar decrease in systemic vitamin E levels in placebo-treated dogs was observed by Natale et al 24 in a cardiac arrest model of complete cerebral ischemia. However, in that study, cardiac arrest would induce ischemia and, possibly, free radical generation in all organ systems during the reperfusion period. A decrease in systemic vitamin E levels in placebo-treated animals would thus predominantly reflect vitamin E utilization in organ systems other than the brain. It is not suggested, however, that the systemic vitamin E levels measured in the present study reflect levels in the CNS. Gearly, a directly measured decrease in brain vitamin E levels in placebo-treated animals would be the most suggestive of ischemia/reperfusion-related free radical activity, but such measurements are not feasible in a neurologic outcome study.
The success of U74006F, a highly efficient free radical scavenging agent, in improving neurologic outcome in this canine model of complete cerebral ischemia is in marked contrast to previous results obtained in a similar model using deferoxamine and a combination of superoxide dismutase and catalase. 1718 Possible explanations for the difference in outcome between our U74006F-treated dogs and that obtained in the superoxide dismutase and catalase study are either that the concentrations of superoxide dismutase and catalase were inadequate at the time of reperfusion or that the agents were not delivered to key sites of free radical generation and damage such as the endothelial membrane and the intracellular space. Both superoxide dismutase and catalase are rapidly cleared by the kidneys, leading to circulatory half-lives of only 6-10 minutes following intravenous injection. 35 In addition, while less-reactive oxygen free radical species generated within a cell occasionally diffuse out of the cell, 36 more highly reactive oxygen free radicals diffuse only short distances before reacting with cellular components. 37 It is unlikely, therefore, that agents that are only poorly transported across cell membranes such as exogenous superoxide dismutase and catalase 38 and that have very short plasma half-lives would be effective in treating possible free radical-related postischemic neurologic damage. Incorporation of superoxide dismutase into liposomes 38 or conjugation of superoxide dismutase and catalase with polyethylene glycol 39 increases the plasma half-life of these agents (from < 10 minutes to 40 hours) and improves the efficiency with which these enzyme free radical scavengers move across cell membranes. 38 
"
39 Interestingly, when rats were pretreated with polyethylene glycol-conjugated superoxide dismutase and catalase, a reduction in infarct size was observed in a rat model of focal cerebral ischemia. 13 While the effect of such a treatment on neurologic outcome in this animal model or a global model of complete cerebral ischemia is unknown, the results indicate that superoxide and hydrogen peroxide contribute to postischemic brain injury. The absence of a protective effect for deferoxamine, 17 which inefficiently crosses the bloodbrain barrier, 40 may be due to inadequate delivery to the CNS following systemic administration. In addition, deferoxamine is a less potent inhibitor of lipid Strobe Vol 22, No 7 July 1991 peroxidation than U74006F. 20 It is also possible that much of the oxygen free radical generation that occurs within a cell is not iron-related. 41 Another possible explanation for the difference between the results of the present study and the failure of superoxide dismutase, catalase, and deferoxamine pretreatment to improve neurologic outcome is that free radicals play an extremely minor role in postischemic reperfusion neurologic injury. The beneficial effects of U74006F may thus be unrelated to its free radical scavenging effect and may be due to an as-yet undefined pharmacologic action of the drug. U74006F decreases postischemic hypoperfusion in a feline model of complete cerebral ischemia, 42 an effect that may be unrelated to its free radical scavenging properties and that might contribute to an improved neurologic outcome.
